The content on this site is intended for healthcare professionals only
Dr Josep Tabernero speaks to ecancer about the SUNLIGHT study.
This study investigated trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer.
The study found that trifluridine/tipiracilTPI plus bevacizumab provides a statistically significant and clinically meaningful 3.3-month improvement in overall survival, extending mOS up to 10.8 months, with a 39% reduction in the HR of death in patients with refractory mCRC and with a predictable and acceptable safety profile.
He concludes by discussing the clinical impact of these results.
Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
